Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Island PharmaceuticalsASX:ILA -2.08%33 Market Cap is A$142.04 Mil as of Jul. 14, 2026. GuruFocus rates ASX:ILA with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 1,423 Biotechnology companies, Island Pharmaceuticals ranks worse than 52.35% on this metric.
Island Pharmaceuticals's quarterly market cap
increased
from Dec. 2024 (A$30.87 Mil) to Jun. 2025 (A$33.05 Mil) and
increased
from Jun. 2025 (A$33.05 Mil) to Dec. 2025 (A$115.69 Mil).
Island Pharmaceuticals's annual market cap
increased
from Jun. 2023 (A$7.72 Mil) to Jun. 2024 (A$9.76 Mil) and
increased
from Jun. 2024 (A$9.76 Mil) to Jun. 2025 (A$33.05 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Island Pharmaceuticals's Enterprise Value for Today is A$140.80 Mil.
Island Pharmaceuticals (ASX:ILA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:ILA vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Island Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Island Pharmaceuticals Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Island Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where Island Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Island Pharmaceuticals's Market Cap for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Island Pharmaceuticals (ASX:ILA) has a Market Cap of A$142.04 Mil as of Jul. 14, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Island Pharmaceuticals and its competitors. According to the industry distribution chart, Island Pharmaceuticals ranks #745 out of 1423 companies in the Biotechnology industry, placing it in the top 52.4%.
Is Island Pharmaceuticals' Market Cap too high?
Island Pharmaceuticals' current Market Cap is A$142.04 Mil. Based on the distribution chart, Island Pharmaceuticals ranks #745 out of 1423 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Island Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Island Pharmaceuticals' Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Island Pharmaceuticals ranks #745 out of 1423 companies for Market Cap. This places Island Pharmaceuticals in the lower half of its industry. The industry median Market Cap is 115.88. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 115.88, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Island Pharmaceuticals and its competitors. For the Biotechnology industry, the median Market Cap is 115.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Island Pharmaceuticals's current Market Cap is A$142.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Island Pharmaceuticals stock overvalued right now?
Island Pharmaceuticals (ASX:ILA) has a current Market Cap of A$142.04 Mil. The current Market Cap is A$142.04 Mil. Island Pharmaceuticals' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Island Pharmaceuticals (ASX:ILA), the current Market Cap is A$142.04 Mil as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Island Pharmaceuticals Ltd is a drug research and repurposing company focused on developing preventative or therapeutic drugs for viral infections, public health, or biosecurity threats. The company is following a dual development plan for its assets, ISLA-101 and Galidesivir. Its product candidate, ISLA-101, is being repurposed for the prevention and treatment of dengue fever and other mosquito-borne (or vector) borne diseases. Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika, and Yellow fever viruses, with unmet medical needs. The company operates in a single segment, being research and development activities in Australia and the United States of America.
33GF Score
Get the complete analysis for ASX:ILA
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ILA has been successfully added to your 
